Nanozymes, methods of making nanozymes, and methods of using nanozymes

A pharmaceutical formulation comprising:

• a nanozyme, wherein the nanozyme comprises:
• a shell surrounding a hollow core configured to receive a compound, wherein the shell comprises:
• a single stranded DNA (ssDNA) recognition moiety selected from the group consisting of:
• a polynucleotide set forth in SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, SEQ ID NO:
• 5, SEQ ID NO:
• 16, SEQ ID NO:
• 17, and combinations thereof, wherein the ssDNA recognition moiety comprises an alkylthiol-terminated propargyl ether modified poly-thymine polynucleotide;
• wherein the alkylthiol-terminated, propargyl ether modified poly-thymine polynucleotide comprises one or more propargyl ether groups coupled via an amidohexylacrylamido linker to the 5′ position of one or more thymine bases, and wherein the ssDNA recognition moiety specifically binds, through reverse complementary binding, a polynucleotide selected from the group consisting of:
• a c-MET mRNA, a conserved Glycoprotein (cGP) region of a positive RNA strand of Ebola virus, a cGP region of a negative RNA strand of Ebola virus, a survivin mRNA, and a bcl 2 mRNA;
• an endoribonuclease-oligonucleotide complex comprising an endoribonuclease coupled to an alkylthiol-terminated, propargyl ether modified poly-thymine polynucleotide, wherein the alkylthiol-terminated, propargyl ether modified poly-thymine polynucleotide comprises one or more propargyl ether groups coupled via an amidohexylacrylamido linker to the 5′ position of one or more thymine bases, and
• wherein at least some of the propargyl ether groups on the alkylthiol-terminated propargyl ether modified poly-thymine polynucleotide of the endoribonuclease-oligonucleotide complex, of the ssDNA recognition moiety, or of the endoribonuclease-oligonucleotide complex and the ssDNA recognition moiety are crosslinked;
• and
• a pharmaceutically acceptable carrier.

A method comprising:

• administering a nanozyme to a subject, wherein the nanozyme comprises a shell surrounding a hollow core configured to receive a compound, wherein the shell comprises:
• a single stranded DNA (ssDNA) recognition moiety selected from the group consisting of:
• a polynucleotide set forth in SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, SEQ ID NO:
• 5, SEQ ID NO:
• 16, SEQ ID NO:
• 17, and combinations thereof, wherein the ssDNA recognition moiety is functionalized with comprises an alkylthiol-terminated propargyl ether modified poly-thymine polynucleotide;
• wherein the alkylthiol-terminated, propargyl ether modified poly-thymine polynucleotide comprises one or more propargyl ether groups coupled via an amidohexylacrylamido linker to the 5′ position of one or more thymine bases, and wherein the ssDNA recognition moiety specifically binds, through reverse complementary binding, a polynucleotide selected from the group consisting of:
• a c-MET mRNA, a conserved Glycoprotein (cGP) region of a positive RNA strand of Ebola virus, a cGP region of a negative RNA strand of Ebola virus, a survivin mRNA, and a bcl 2 mRNA, and an endoribonuclease-oligonucleotide complex comprising an endoribonuclease coupled to an alkylthiol-terminated, propargyl ether modified poly-thymine polynucleotide, wherein the alkylthiol-terminated, propargyl ether modified poly-thymine polynucleotide comprises one or more propargyl ether groups coupled via an amidohexylacrylamido linker to the 5′ position of one or more thymine bases, and wherein at least some of the propargyl ether groups on the alkylthiol-terminated propargyl ether modified poly-thymine polynucleotide of the endoribonuclease-oligonucleotide complex, of the ssDNA recognition moiety, or of the endoribonuclease-oligonucleotide complex and the ssDNA recognition moiety are crosslinked.